


PHARMACEUTICAL 2020



Ayala Pharmaceuticals Inc. Rank 63 of 358





PHARMACEUTICAL 2020





Ayala Pharmaceuticals Inc. Rank 63 of 358

The relative strengths and weaknesses of Ayala Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ayala Pharmaceuticals Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 70% points. The greatest weakness of Ayala Pharmaceuticals Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 43% points.

The company's Economic Capital Ratio, given in the ranking table, is 202%, being 165% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	36,149
Cost of Goods Sold	0
Intangible Assets	4,575
Liabilities, Current	4,521
Liabilities, Non-Current	1,205
Other Assets	183
Other Compr. Net Income	0
Other Expenses	1,657
Other Liabilities	0
Other Net Income	2,582
Other Revenues	21,319
Property and Equipment	4,350
Research and Development	26,677
Selling, General and Administrative Expense	12,179

Output Variable	Value in 1000 USD
Assets	45,257
Liabilities	5,726
Expenses	40,513
Revenues	21,319
Stockholders Equity	39,531
Net Income	-16,612
Comprehensive Net Income	-16,612
Economic Capital Ratio	202%

